DNA Extraction and Quantification from Biological Evidence

Extraction commonly begins with lysis to disrupt cellular structures and release DNA. Detergents, protein digestion and other treatments depend on the specimen and method. Purification then separates useful nucleic acids from proteins, salts and substrate-associated compounds, with some DNA loss possible at each transfer.

Organic extraction can recover useful DNA but is not an automatic gold standard for every low-level or inhibitor-rich specimen. Chelex preparations are often suitable for validated PCR workflows, although heat denaturation and the preparation’s chemistry make them different from intact double-stranded preparations used in older RFLP work.

Solid-phase extraction includes membrane and magnetic-particle approaches. The presence of a magnet does not identify the binding chemistry. PrepFiler, for example, is described by its manufacturer as using magnetic particles with an optimised multicomponent surface; calling every such product a silica method is inaccurate.

Purification kits may contain hazardous salts, solvents or other reagents. Automation can reduce some manual handling while introducing instrument-specific risks and maintenance requirements. Follow product safety information, and validate the complete laboratory workflow rather than treating a commercial label as proof of performance.

Differential extraction can enrich sperm-associated DNA separately from other cellular material in suitable mixed specimens. A relatively mild first lysis releases DNA from susceptible cells while retaining many sperm heads; the retained material is washed and subjected to a stronger second treatment.

Sperm DNA is tightly packaged with protamines containing disulfide cross-links. A reducing agent such as DTT helps disrupt this resistant packaging during sperm lysis. The relevant distinction concerns sperm chromatin and cellular resistance, rather than a claim that all cross-linked protamines are structural proteins of the nuclear envelope.

The fractions are conventionally called non-sperm and sperm fractions, but these names describe processing. They do not prove exclusive cell types or assign victim and offender roles. Free DNA, damaged sperm, incomplete separation and carry-over can produce mixtures in either fraction.

A sperm-negative specimen may still contain semen-associated material and informative DNA. Azoospermia, vasectomy-related effects, degradation, dilution and sampling can influence the result. The absence of visible sperm does not make differential extraction necessary, useful or successful in every case.

Record the fractionation steps, observations, controls and transfers. Compare profiles under appropriate mixture assumptions instead of inferring purity from the tube label. The decision to fractionate should consider expected benefit, consumption and alternative validated approaches.

Bone and teeth require attention to tissue selection, surface contamination and the balance between DNA recovery and preservation of other evidence. Some methods use powder and demineralisation; others use targeted or less destructive sampling. Complete pulverisation and liquid-nitrogen grinding are not mandatory for every skeletal examination.

Hair roots and shafts differ in cellular composition and DNA condition. Rootless shafts can contain fragmented nuclear DNA as well as mitochondrial DNA, so the absence of an attached root does not establish that nuclear testing is impossible. The suitable method depends on demonstrated recovery and analytical capability.

Contact traces can contain very small, unevenly distributed amounts of cellular and extracellular DNA. Fewer transfers and suitable consumables may improve recovery, but no fixed concentration defines every touch sample. Cleaning up an extract can remove inhibitors while also losing template.

Fabric dyes, soil compounds, haem-associated material and substances introduced during processing can affect downstream assays. A method that performs well on one substrate may behave differently on another. Extraction blanks and appropriate controls help distinguish laboratory background from sample findings without resolving every contamination possibility.

A poor result may reflect low starting quantity, unsuccessful lysis, binding loss, degradation or inhibition. These alternatives call for different responses. Re-extraction can consume valuable material and should follow a reasoned, documented assessment rather than an automatic repeat-until-match strategy.

Real-time PCR monitors an amplification-associated signal during cycling. A calibration series connects a measured threshold cycle, often called Cq or Ct, to estimated starting target quantity. Earlier threshold crossing usually corresponds to more target when comparisons use compatible conditions and acceptable reaction performance.

The output measures the assay’s target rather than every DNA molecule in the tube. Human-specific targets can distinguish useful human signal from much microbial or animal DNA, subject to the assay’s actual specificity. Multicopy target variation and calibration assumptions also affect estimates.

Some forensic assays measure autosomal and Y-chromosomal targets, include an internal PCR control and compare shorter and longer targets. These features are not universal. Plexor HY measures total human and male DNA with an internal control; PowerQuant additionally supports a short/long-target assessment of integrity.

A degradation index compares assay-defined estimates associated with different target lengths. It is not simply the ratio of their amplification efficiencies or raw cycle values. Direction, target design, thresholds and usable ranges follow the actual product and laboratory validation.

An internal control can reveal an unexpected assay response, including inhibition, but a delayed signal does not uniquely identify one inhibitor or mechanism. A normal control with no human signal does not prove absolute DNA absence: low quantity, target damage, sampling and other limitations remain possible.

Assess standards, negatives and controls before accepting sample values. Do not invent a universal Cq-to-concentration conversion, and distinguish a numerical estimate near the detection limit from a reliably quantified result. Record relevant dilution factors and whether a reported value describes the original extract or a diluted preparation.

The basic calculation is input volume = desired DNA mass divided by extract concentration. Both quantities must use consistent units. For a hypothetical extract at 0.08 ng/µL and a target mass of 0.5 ng, the calculated volume is 6.25 µL, provided that volume and input are suitable for the validated STR reaction.

The target mass is kit- and workflow-specific. A concentration is not the total mass available: multiplying by extract volume estimates the amount in the tube, while only the aliquot added reaches the reaction. Quantification uncertainty and heterogeneous mixtures limit the precision of these calculations.

Dilution can reduce inhibitors but also reduces DNA concentration. Cleanup may help but can lose template. Choosing between them requires the control pattern, available quantity, downstream sensitivity and validated alternatives. Adding BSA, changing enzyme or increasing cycle number is not an unrestricted case-by-case remedy.

Fragmentation presents a different problem. A high short-target estimate with poor long-target recovery can justify considering validated shorter-target typing or sequencing methods. Sequencing does not reconstruct missing molecules, and a universal degradation-index cutoff does not decide every sample’s fate.

Low-template results can show stochastic effects such as allele dropout and imbalance, with contamination particularly consequential. More cycles do not create missing original information. Record the input choice, controls, deviations and interpretation limitations, including decisions not to consume the remaining specimen.

Maintain the connection between the received item, sampled area, lysate, fractions, extract and aliquots. Identifiers, handling records and retained portions support review and possible further testing. A missing signature or recording discrepancy needs investigation, but does not create automatic inadmissibility in every legal system.

Separate activities with different contamination risks, use appropriate consumables and protective practices, and evaluate blanks and other controls. UV exposure is one possible validated decontamination measure, not a guarantee that a surface is DNA-free. Elimination samples can help investigate associations without proving a contamination route by themselves.

In the US, applicable FBI quality requirements and laboratory policies address validation, records and review. In the UK, the relevant national legal system and applicable forensic quality framework matter; England and Wales have a statutory regulator. India and other countries have their own legal and accreditation arrangements.

ISO/IEC 17025 concerns competence within an assessed scope. It is not synonymous with FBI accreditation or universal courtroom approval. The record should allow a competent reviewer to assess the actual work, including problematic controls and reasonable alternative explanations.

Preservation before extraction remains important, but a single cold-storage rule is unsafe. Dry stains, liquid blood, tissue and purified extracts need different conditions. Coordinate with the receiving laboratory and document storage and excursions rather than automatically freezing every swab or refrigerating every item.